DC-CIK免疫治疗联合TACE介入治疗晚期肝癌的临床研究

doi:10.3969/j.issn.1009-976X.2014.05.002

岭南现代临床外科 ›› 2014, Vol. 14 ›› Issue (05): 505-508.DOI: 10.3969/j.issn.1009-976X.2014.05.002

DC-CIK免疫治疗联合TACE介入治疗晚期肝癌的临床研究

祖余琪¹,薛平²,蒋小峰¹,温子龙²,张大伟¹

1. 广州医科大学附属第二医院
2. 广州医学院第二附属医院

通讯作者: 薛平
基金资助:
广东省科技计划项目

Clinical research on treating advanced stage hepatocarcinoma with DC-CIK immunotherapy combined with TACE interventional therapy

ZuYuqi, Xue Ping, Jiang Xiaofeng, Wen Zilong, Zhang Dawei

Received:2014-07-01 Revised:2014-09-25 Online:2014-10-20 Published:2014-10-20

摘要/Abstract

摘要：

【摘要】〓目的〓探讨DC-CIK细胞免疫治疗联合介入治疗晚期肝癌的临床疗效。方法〓选择晚期原发性肝癌患者112例为研究对象,根据患者自愿情况分为TACE联合DC-CIK细胞免疫治疗组(A组,n=64)和TACE治疗组(B组,n=48),观察治疗前后血常规、肿瘤标志物、免疫功能及治疗效果。结果〓A组缓解率明显高于B组(78.12% VS 47.92%);治疗前后CD3+、CD4+、CD8+、CD19+、NK、CD3+/CD4+、CD3+/CD8+增加或减少值均高于B组;随访6个月、12个月,A组死亡病例明显低于B组(6.25% VS 16.67%, 1.78% VS 12.82%),但两组18个月的死亡病例数比较没有差异。结论〓TACE联合DC-CIK细胞免疫治疗一定程度上可改善免疫功能,提高近期疗效。

关键词: 晚期肝癌, TACE, DC-CIK, 肿瘤标志物, 免疫功能

Abstract: 【Abstract】〓Objective〓To investigate the clinical effectiveness of transcatheter arterial chemoem-bolization (TACE) combined with DC-CIK in treating advanced stage hepatocarcinoma. Methods〓112 patients with advanced stage hepatocarcinoma were included in the study..Among them,64 cases received TACE combined with DC-CIK (group A) and 48 cases underwent TACE alone (group B). Blood routine, tumor makers, immune function were detected, analyzed in all patients and compared between two groups. Results〓The serum CD3+, CD4+, CD8+, CD19+, NK, CD3+/CD4+, CD3+/CD8+ cells in A group were increased than that in B group (P<0.05). The number of patients who were demonstrated remission and partial remission was increased in A group than that in B group(P<0.05). The death mumber in A group was less than in group at 6 months and 12 months of follow-up and no difference was found at 18 months of follow-up. Conclusion〓To a certain degree, TACE combined with DC-CIK would improve the immune function,increase in the near future curative effect for patients with advanced stage hepatocarcinoma.

Key words: Advanced hepatocarcinoma, TACE, DC-CIK, Tumor makers, Immune function　

中图分类号:

R735.7

祖余琪薛平蒋小峰温子龙张大伟. DC-CIK免疫治疗联合TACE介入治疗晚期肝癌的临床研究[J]. 岭南现代临床外科, 2014, 14(05): 505-508.

ZuYuqi, Xue Ping, Jiang Xiaofeng, Wen Zilong, Zhang Dawei. Clinical research on treating advanced stage hepatocarcinoma with DC-CIK immunotherapy combined with TACE interventional therapy[J]. Lingnan Modern Clinics in Surgery, 2014, 14(05): 505-508.

参考文献

[1] Banchereanl J，Steinman R．Dendritic cells and the control of
immunity[J]．Nature，1998，392：245．
[2] Schott M，Seisslar J．Dendritic cell vaccination：new hope for
thetreatment of metastasized endocrine malignancies[J]．
Trends Endocrinal Metab，2003，14(4)：156
[3]钱其军, 吴孟超. 肿瘤过继细胞治疗--老故事新演绎[J]. 中国肿瘤生物治疗杂志, 2011, (18): 1-5.
[4]杨秉辉，任正刚，汤钊猷.我国肝癌“临床相”30年变迁—原发性肝癌3250例的对比研究.中华医学杂志，2003,83:1053-1057
[5]Bruix J.Treatment of hepatocellular carcinoma.Hepatology,1997,25:259-262
[6]汤钊猷.现代肿瘤学.第3版.上海：复旦大学出版社，2011:890-934
[7]吕嘉玲，杜明瑞.肝动脉化疗栓塞治疗原发性肝癌的预后因素分析.实用放射学杂志，2012，28（1）：114-118
[8]Rosenberg SA,Dudley ME.Adoptive cell therapy for the treatment of patients with metastatic melanoma[J].Curr Opin Immunol,2009,21(2):233-240.
[9]Sangiolo D.Cytokine induced killer cells as promising immunotherapy for solid tumor[J].J Cancer,2011,2:363-368
[10]Niam M,Linn YC.Fook Chong S,et al.Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy[J].Exp Hematol .2011,39(9):897-903.
[11]Lu XC,Yang B,Yu RL,et al.Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse laege B-cell lymphoma[J]. Cell Biochem Biophys,2012,62,(1):257-265.
[12]Yu J,Ren X,Li H,et al.Synergistic effect of CH-296 and interferon gamma on cytokine-induced killer cells expansion for patients with advanced-stage malignant solid tumors[J]. Cancer Biother Radiopharm,2011,26(4):485-494.

DC-CIK免疫治疗联合TACE介入治疗晚期肝癌的临床研究

Clinical research on treating advanced stage hepatocarcinoma with DC-CIK immunotherapy combined with TACE interventional therapy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

[1]	管玉婷, 曾国斌, 陈建平, 吴雄健. 预防高危因素患者肝癌切除术后复发的治疗进展[J]. 岭南现代临床外科, 2023, 23(02): 193-199.
[2]	伍隽华, 谭慧敏, 左超海, 邝乃乐, 余杰雄, 陈云扬. TACE治疗预防肝癌术后复发的临床分析[J]. 岭南现代临床外科, 2021, 21(04): 397-404.
[3]	罗启杰胡泽民. 肝细胞癌生物标记物的研究进展[J]. 岭南现代临床外科, 2017, 17(02): 230-235.
[4]	黄楚媚曾林涓苏红黄开红. 新肿瘤标志物—长链非编码RNA分子机制及其与肿瘤关系研究进展[J]. 岭南现代临床外科, 2015, 15(06): 743-748.
[5]	刘毅豪. 不同PSA相关肿瘤标志物在前列腺癌中的诊断价值[J]. 岭南现代临床外科, 2015, 15(04): 494-497.
[6]	李国文曾山崎王成兴李莉珊叶华杨平. 糖链抗原724、癌胚抗原在结直肠癌术后患者血清中的表达及相关性研究[J]. 岭南现代临床外科, 2014, 14(02): 143-146.
[7]	祖余琪薛平. DC-CIK过继细胞免疫治疗原发性肝癌的研究进展[J]. 岭南现代临床外科, 2014, 14(02): 214-216.
[8]	黎艳欢魏娟. 经皮肝动脉插管化疗栓塞术治疗肝癌患者的同步营养干预[J]. 岭南现代临床外科, 2013, 13(03): 270-.
[9]	吴兴平曾秋耀李林芳曾敬吴明玮. 血清中神经特异性烯醇化酶对肺癌患者的临床意义[J]. 岭南现代临床外科, 2012, 12(03): 199-201.